| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Claudin-1[1]
PDS-0330 specifically targets claudin-1, a key component of tight junctions that is frequently overexpressed in colorectal cancer and associated with poor prognosis. By binding to claudin-1 with a Kd of 22.9 μM in MST binding assays, PDS-0330 impairs the interaction between claudin-1 and phosphorylated Src (pSrc)/Src. This disruption alters downstream survival signaling pathways that are critical for cancer cell proliferation and metastasis. The compound's mechanism of action involves blocking the oncogenic functions of claudin-1 rather than its structural role in tight junctions. |
|---|---|
| ln Vitro |
In vitro studies demonstrate that PDS-0330 is a potent claudin-1 inhibitor with a Kd of 22.9 μM as determined by microscale thermophoresis (MST) binding assays. The compound effectively interferes with claudin-1/Src association in cell-based systems, leading to the alteration of survival signaling pathways. PDS-0330 inhibits colorectal cancer cell progression and metastasis in vitro by disrupting the oncogenic signaling mediated by the claudin-1/Src axis. The compound's activity is specific to claudin-1, as it is described as a specific inhibitor of this target.
|
| ln Vivo |
In vivo efficacy data for PDS-0330 have not been extensively detailed in the published literature. As a claudin-1 inhibitor that interferes with Src association and inhibits CRC progression and metastasis, PDS-0330 is expected to demonstrate antitumor activity in animal models of colorectal cancer. The compound's ability to alter survival signaling pathways suggests potential for reducing tumor growth and preventing metastatic spread in vivo. However, specific in vivo study results, including dosing regimens, administration routes, and efficacy endpoints, have not been reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for PDS-0330 typically involve microscale thermophoresis (MST) to measure the binding affinity between the compound and claudin-1. In these assays, a fixed concentration of fluorescently labeled claudin-1 is titrated with increasing concentrations of PDS-0330, and the change in thermophoretic mobility is measured to calculate the dissociation constant (Kd). The reported Kd value for PDS-0330 binding to claudin-1 is 22.9 μM. Additional binding studies may employ surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to further characterize the interaction.
|
| Cell Assay |
In vitro cellular assays for PDS-0330 typically utilize colorectal cancer cell lines that express claudin-1. Cells are treated with varying concentrations of the compound, and the effects on claudin-1/Src association are assessed by co-immunoprecipitation or proximity ligation assays. Downstream survival signaling pathway modulation is evaluated by Western blot analysis of phosphorylated signaling proteins. Cell proliferation is measured using MTT or CCK-8 assays, while cell migration and invasion are assessed using transwell or wound-healing assays. The compound's specificity is confirmed by comparing its effects in claudin-1-expressing versus non-expressing cells.
|
| Animal Protocol |
In vivo animal experiments for PDS-0330 have not been extensively reported. Based on its mechanism of action as a claudin-1 inhibitor that interferes with Src association and inhibits colorectal cancer progression and metastasis, potential in vivo studies would involve subcutaneous or orthotopic xenograft mouse models of colorectal cancer. Tumor-bearing mice would be treated with PDS-0330 via oral or intraperitoneal administration, and endpoints would include tumor volume measurement, metastatic burden assessment, survival analysis, and histopathological examination of tumor tissues for claudin-1/Src pathway modulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of PDS-0330 have not been extensively characterized in the published literature. The compound has a molecular weight of 423.49 g/mol and a molecular formula of C₂₅H₁₇N₃O₂S. As a small molecule with heterocyclic aromatic moieties, it is expected to have reasonable membrane permeability and oral bioavailability. The compound is typically stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years, and in solvent at -80°C for 6 months or at -20°C for 1 month. Purity is ≥98%.
|
| Toxicity/Toxicokinetics |
Dedicated toxicological data for PDS-0330 have not been published, as the compound is intended for research use only and not for therapeutic administration to patients. The compound's specificity for claudin-1 suggests a potentially manageable off-target toxicity profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose toxicity studies would be required for therapeutic development. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Fatima I, et al. Identification and characterization of a first-generation inhibitor of claudin-1 in colon cancer progression and metastasis. Biomed Pharmacother. 2023 Mar;159:114255.
|
| Additional Infomation |
PDS-0330 (CAS# 2904682-19-3, molecular formula C₂₅H₁₇N₃O₂S, molecular weight 423.49) is a first-generation, specific small-molecule claudin-1 inhibitor that binds with a Kd of 22.9 μM. It interferes with claudin-1/Src association and inhibits colorectal cancer progression and metastasis. The compound is for research use only. No clinical trials or regulatory approvals have been identified. Purity ≥98%. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Molecular Formula |
C25H17N3O2S
|
|---|---|
| Molecular Weight |
423.486384153366
|
| Exact Mass |
423.104
|
| CAS # |
2904682-19-3
|
| PubChem CID |
163360883
|
| Appearance |
White to light yellow solid powder
|
| LogP |
6.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
651
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C=C(C=CC2=C1)C(=O)NC(=S)NC3=CC=C(C=C3)C4=NC5=CC=CC=C5O4
|
| InChi Key |
DRGVVUJKZXEUFA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H17N3O2S/c29-23(19-10-9-16-5-1-2-6-18(16)15-19)28-25(31)26-20-13-11-17(12-14-20)24-27-21-7-3-4-8-22(21)30-24/h1-15H,(H2,26,28,29,31)
|
| Chemical Name |
N-[[4-(1,3-benzoxazol-2-yl)phenyl]carbamothioyl]naphthalene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 4 mg/mL (9.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3613 mL | 11.8067 mL | 23.6133 mL | |
| 5 mM | 0.4723 mL | 2.3613 mL | 4.7227 mL | |
| 10 mM | 0.2361 mL | 1.1807 mL | 2.3613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
